Abstract

The overall goal of the Vaccine Technologies Core (VTC) is to provide highly specialized expertise in the areas of eukaryotic recombinant protein production, alphavirus RNA replicon and adenovirus vector technologies, novel adjuvants, vaccine formulation and immunogenicity screening in small animals. This expertise will be used to produce and characterize state-of-the-art vaccine components to be utilized in all of the projects described in this multi-program project proposal. Specifically, the core will provide novel recombinant HIV Env proteins (as well as novel adjuvants and formulations thereof) and recombinant viral vectors for evaluation in the Projects and Core C. In addition, novel mimotopes, VLPs and gp41-based immunogens from Projects 2 and 3 will be formulated with novel adjuvants to enhance potency and breadth of immune responses. The core will also consolidate the screening of these novel immunogens and adjuvants in rabbits for their ability to induce neutralizing antibodies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI066287-04
Application #
7923782
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
4
Fiscal Year
2009
Total Cost
$908,875
Indirect Cost

  Institution

Name
Novartis Vaccines and Diagnostics, Inc.
Department
Type
DUNS #
046866463
City
Cambridge
State
MA
Country
United States
Zip Code
02139

  Publications

Shen, Xiaoying; Bogers, Willy M; Yates, Nicole L et al. (2017) Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. J Virol 91:
Bogers, Willy M J M; Barnett, Susan W; Oostermeijer, Herman et al. (2017) Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. J Virol 91:
Bruun, Tim-Henrik; Grassmann, Veronika; Zimmer, Benjamin et al. (2017) Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins. MAbs 9:1052-1064
Liang, Frank; Lindgren, Gustaf; Sandgren, Kerrie J et al. (2017) Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med 9:
Vassell, Russell; He, Yong; Vennakalanti, Prasad et al. (2015) Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. PLoS One 10:e0128562
Bogers, Willy M; Oostermeijer, Herman; Mooij, Petra et al. (2015) Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211:947-55
Tuero, Iskra; Mohanram, Venkatramanan; Musich, Thomas et al. (2015) Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. PLoS Pathog 11:e1005101
Brito, Luis A; Chan, Michelle; Shaw, Christine A et al. (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 22:2118-29
Kassa, Aemro; Dey, Antu K; Sarkar, Pampi et al. (2013) Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. PLoS One 8:e76139
Dey, Antu K; Burke, Brian; Sun, Yide et al. (2012) Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. PLoS One 7:e30233

Showing the most recent 10 out of 24 publications